Ionis Pharmaceuticals (IONS) Stock Statistics & Valuation Metrics

Ionis Pharmaceuticals has a market cap or net worth of $12.23B. The enterprise value is $14.69B.

Ionis Pharmaceuticals has 165,192,020 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ionis Pharmaceuticals’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -11.96%.

The current PE Ratio of Ionis Pharmaceuticals is ―. Ionis Pharmaceuticals’s PEG ratio is 1.53.

In the last 12 months, Ionis Pharmaceuticals had revenue of 944.00M and earned -381.00M in profits. Earnings per share was -2.38.

In the last 12 months, operating cash flow was -268.58M and capital expenditures -51.44M, giving a free cash flow of -320.03M billion.

Ionis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Ionis Pharmaceuticals upcoming earnings date is May 6, 2026, Before Open (Confirmed).

Ionis Pharmaceuticals as a current ratio of 3.83, with Debt / Equity ratio of 534.53%

In the past 12 months, Ionis Pharmaceuticals has paid 1.00M in taxes.

Ionis Pharmaceuticals EV to EBITDA ratio is -51.96, with an EV/FCF ratio of -46.56.

Ionis Pharmaceuticals has $2.68B in cash and marketable securities with $2.61B in debt, giving a net cash position of $62.67M billion.

Gross margin is 98.31%, with operating margin of -40.47%, and net profit margin of -40.36%.

The average price target for Ionis Pharmaceuticals is $95.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy